CA2362940A1 - Traitement de l'infecondite - Google Patents
Traitement de l'infecondite Download PDFInfo
- Publication number
- CA2362940A1 CA2362940A1 CA002362940A CA2362940A CA2362940A1 CA 2362940 A1 CA2362940 A1 CA 2362940A1 CA 002362940 A CA002362940 A CA 002362940A CA 2362940 A CA2362940 A CA 2362940A CA 2362940 A1 CA2362940 A1 CA 2362940A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- hormone
- oocytes
- mas
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 17
- 208000000509 infertility Diseases 0.000 title claims description 8
- 230000036512 infertility Effects 0.000 title claims description 7
- 231100000535 infertility Toxicity 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 238000003744 In vitro fertilisation Methods 0.000 claims abstract description 11
- 210000000287 oocyte Anatomy 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 41
- 230000035800 maturation Effects 0.000 claims description 26
- 239000000556 agonist Substances 0.000 claims description 24
- 239000005557 antagonist Substances 0.000 claims description 23
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 229940088597 hormone Drugs 0.000 claims description 17
- 239000005556 hormone Substances 0.000 claims description 17
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 claims description 16
- 235000013601 eggs Nutrition 0.000 claims description 16
- 239000000960 hypophysis hormone Substances 0.000 claims description 15
- 239000000601 hypothalamic hormone Substances 0.000 claims description 14
- 229940043650 hypothalamic hormone Drugs 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 108010086677 Gonadotropins Proteins 0.000 claims description 9
- 102000006771 Gonadotropins Human genes 0.000 claims description 9
- 239000002622 gonadotropin Substances 0.000 claims description 9
- 210000001136 chorion Anatomy 0.000 claims description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 230000035558 fertility Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000001592 luteinising effect Effects 0.000 claims description 2
- 230000027758 ovulation cycle Effects 0.000 claims description 2
- 230000001360 synchronised effect Effects 0.000 claims description 2
- 230000021121 meiosis Effects 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 229940094892 gonadotropins Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- -1 e.g. Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010023204 Joint dislocation Diseases 0.000 description 2
- 108010057021 Menotropins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 108010021717 Nafarelin Proteins 0.000 description 2
- 108010020661 Profasi Proteins 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000002474 gonadorelin antagonist Substances 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940086546 synarel Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940064298 pregnyl Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Aux fins de l'invention, il est possible d'améliorer la fécondation in vitro par adjonction d'un composé activant la méiose.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900255 | 1999-02-24 | ||
| DKPA199900255 | 1999-02-24 | ||
| DKPA199901310 | 1999-09-16 | ||
| DKPA199901310 | 1999-09-16 | ||
| PCT/DK2000/000074 WO2000050066A1 (fr) | 1999-02-24 | 2000-02-23 | Traitement de l'infecondite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2362940A1 true CA2362940A1 (fr) | 2000-08-31 |
Family
ID=26063622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002362940A Abandoned CA2362940A1 (fr) | 1999-02-24 | 2000-02-23 | Traitement de l'infecondite |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2362940A1 (fr) |
| IL (1) | IL143729A0 (fr) |
| NO (1) | NO20014093L (fr) |
-
2000
- 2000-02-23 IL IL14372900A patent/IL143729A0/xx unknown
- 2000-02-23 CA CA002362940A patent/CA2362940A1/fr not_active Abandoned
-
2001
- 2001-08-23 NO NO20014093A patent/NO20014093L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL143729A0 (en) | 2002-04-21 |
| NO20014093D0 (no) | 2001-08-23 |
| NO20014093L (no) | 2001-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6281013B1 (en) | Treatment of Infertility | |
| US6585982B1 (en) | Treatment of infertility | |
| Chian et al. | Pregnancies resulting from in vitro matured oocytes retrieved from patients with polycystic ovary syndrome after priming with human chorionic gonadotropin | |
| US5869081A (en) | Progesterone vaginal ring for treatment of infertility | |
| US20060069031A1 (en) | Use of gnrh agonists to support the luteal phase during infertility treatment | |
| Zhang et al. | Effects of follicle‐stimulating hormone and ovarian steroids during vitro meiotic maturation on fertilization of rat oocytes | |
| TW201945024A (zh) | 用於經控制之卵巢刺激的組成物 | |
| RU2221588C2 (ru) | Способ терапевтического лечения бесплодия | |
| Ubaldi et al. | Ovulation by repeated human chorionic gonadotrophin in'empty follicle syndrome'yields a twin clinical pregnancy. | |
| CZ299820B6 (cs) | Farmaceutický kit pro terapii infertility programováním kontrolované ovariální stimulace a asistovaných reprodukcních postupu | |
| Fauser | Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol | |
| JP2005530818A (ja) | 卵巣過剰刺激の制御方法及び当該方法に利用する医薬キット | |
| CA2362940A1 (fr) | Traitement de l'infecondite | |
| ZA200104803B (en) | Treatment of infertility. | |
| CN113456801A (zh) | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 | |
| Serhal | Oocyte donation and surrogacy | |
| ZA200104653B (en) | Treatment of infertility. | |
| Hizkiyahu et al. | IVF Protocols: Past, Present, and Future | |
| KR102821987B1 (ko) | 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물 | |
| MXPA01008452A (en) | Treatment of infertility | |
| CN1414860A (zh) | 不孕症的治疗 | |
| US20030153808A1 (en) | Implantation rate using ff-mas | |
| RU2001125943A (ru) | Лечение бесплодия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |